 |
|
Analysis and Reporting of Factorial Trials
A Systematic Review
Finlay A. McAlister, MD, MSc;
Sharon E. Straus, MD, MSc;
David L. Sackett, MD, MSc;
Douglas G. Altman, DSc
JAMA. 2003;289:2545-2553.
Context Although factorial trials have become common, standards for the analysis and reporting of such trials have not been established and, despite concerns about the possibility of unrecognized interactions between therapies in factorial trials, the magnitude of this potential problem is unknown.
Objective To examine the rationale, methods, and analysis of randomized factorial trials.
Data Sources and Study Selection We searched MEDLINE, EMBASE, and the Cochrane Controlled Trials Register using the terms factorial, interaction, 2 x 2, 2 by 2, and incremental to identify factorial randomized trials published from January 2000 to July 2002. To identify trials missed by the electronic search, we performed a hand search of English-language trials in a defined topic area (using the term myocardial ischemia [exp]) listed in MEDLINE (1966-2002), EMBASE (1980-2002), and the Cochrane Controlled Trials Register, as well as all trials in any topic area published in December 2000, excluding trials reporting only continuous surrogate end points. The final set of 33 eligible publications described 29 unique trials.
Data Extraction Two investigators independently identified factorial trials, generated a list of items affecting validity of results, and abstracted these items from each trial.
Data Synthesis The sensitivity of electronic searching for identifying factorial trials was 76%. Our 3-pronged search strategy identified 44 factorial trials with clinically important binary outcomes: 36 (82%) were done for reasons of efficiency (testing 2 interventions in the same patient population), and 8 (18%) were done to assess the incremental benefits of combining the 2 treatments. All but 1 of the trials reported treatment effects by comparing all patients who received treatment A (ie, those receiving either A alone or both A and B) vs all those not receiving treatment A (ie, those receiving either B alone or neither A nor B). Twenty-nine of the 44 trials (66%) reported the data from each of the treatment groups separately; 26 trials (59%) reported testing for interactions between the treatments. Only 2 of 31 (6%) comparisons demonstrated a statistically significant interaction between the 2 treatments.
Conclusions Accurate interpretation of factorial trials depends on the transparent reporting of data for each treatment cell. Despite concerns about unrecognized interactions, our findings suggest that investigators are appropriately restricting their use of the factorial design to those situations in which 2 (or more) treatments do not have the potential for substantive interaction.
Author Affiliations: Division of General Internal Medicine, University of Alberta, Edmonton (Dr McAlister); Division of General Internal Medicine and Geriatrics, University of Toronto, Toronto, Ontario (Dr Straus); Trout Research and Education Centre at Irish Lake, Ontario (Dr Sackett); and Centre for Statistics in Medicine, Oxford, England (Dr Altman).
RELATED ARTICLES
Composite Outcomes in Randomized Trials: Greater Precision But With Greater Uncertainty?
Nick Freemantle, Melanie Calvert, John Wood, Joanne Eastaugh, and Carl Griffin
JAMA. 2003;289(19):2554-2559.
ABSTRACT
| FULL TEXT
Clinical Trials—Multiple Treatments, Multiple End Points, and Multiple Lessons
Michael S. Lauer and Eric J. Topol
JAMA. 2003;289(19):2575-2577.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis
Choy et al.
Ann Rheum Dis 2008;67:656-663.
ABSTRACT
| FULL TEXT
Review: An examination of effect estimation in factorial and standardly-tailored designs
Allore and Murphy
Clin Trials 2008;5:121-130.
ABSTRACT
Chemoprevention of Primary Liver Cancer: A Randomized, Double-Blind Trial in Linxian, China
Qu et al.
JNCI J Natl Cancer Inst 2007;99:1240-1247.
ABSTRACT
| FULL TEXT
Interaction Between Magnesium Sulfate and Acetylsalicylic Acid in the MASH Trial
Chan et al.
Stroke 2007;38:e14-e14.
FULL TEXT
Response to Letter by Chan et al
van den Bergh and on behalf of the MASH study group
Stroke 2007;38:e15-e15.
FULL TEXT
Mortality in Randomized Trials of Antioxidant Supplements for Primary and Secondary Prevention: Systematic Review and Meta-analysis
Bjelakovic et al.
JAMA 2007;297:842-857.
ABSTRACT
| FULL TEXT
Victims of Our Own Success or Quo Vadis Pediatric Anesthesia?
Nichols and Yaster
Anesth. Analg. 2007;104:255-257.
FULL TEXT
Effects of Citalopram and Interpersonal Psychotherapy on Depression in Patients With Coronary Artery Disease: The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) Trial
Lesperance et al.
JAMA 2007;297:367-379.
ABSTRACT
| FULL TEXT
Reducing hazard related falls in people 75 years and older with significant visual impairment: how did a successful program work?
La Grow et al.
Inj. Prev. 2006;12:296-301.
ABSTRACT
| FULL TEXT
Does Neostigmine Administration Produce a Clinically Important Increase in Postoperative Nausea and Vomiting?
Cheng et al.
Anesth. Analg. 2005;101:1349-1355.
ABSTRACT
| FULL TEXT
Randomised controlled trial of prevention of falls in people aged >=75 with severe visual impairment: the VIP trial
Campbell et al.
BMJ 2005;331:817.
ABSTRACT
| FULL TEXT
DECOPI (DEsobstruction COronaire en Post-Infarctus): a randomized multi-centre trial of occluded artery angioplasty after acute myocardial infarction: DECOPI or NOT DECOPI: more smoke on the horizon
Achrafi
Eur Heart J 2005;26:1566-1567.
FULL TEXT
Blood Pressure Control, Drug Therapy, and Kidney Disease
Contreras et al.
Hypertension 2005;46:44-50.
ABSTRACT
| FULL TEXT
Simple Principles of Clinical Trials Remain Powerful
Califf
JAMA 2005;293:489-491.
FULL TEXT
United Kingdom back pain exercise and manipulation (UK BEAM) randomised trial: cost effectiveness of physical treatments for back pain in primary care
UK BEAM Trial Team
BMJ 2004;329:1381.
ABSTRACT
| FULL TEXT
The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease
Ezekowitz et al.
J Am Coll Cardiol 2004;44:1587-1592.
ABSTRACT
| FULL TEXT
Clinical Trials--Multiple Treatments, Multiple End Points, and Multiple Lessons
Lauer and Topol
JAMA 2003;289:2575-2577.
FULL TEXT
|
